Comment
. 2012 Apr;13(4):e141-2; author reply e142.
doi: 10.1016/S1470-2045(12)70113-4.
Epub 2012 Mar 30.
Second-line erlotinib for non-small-cell lung cancer
- PMID: 22469123
- DOI: 10.1016/S1470-2045(12)70113-4
Item in Clipboard
Comment
Second-line erlotinib for non-small-cell lung cancer
Lancet Oncol.
2012 Apr.
No abstract available
Comment on
-
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24. Lancet Oncol. 2012. PMID: 22277837 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
